Skip to main content

Advertisement

Table 1 Clinical phenotypes of 1215 1000IBD participants

From: The 1000IBD project: multi-omics data of 1000 inflammatory bowel disease patients; data release 1

No. of participants 1215
Age (Median ± IQR) 41 ± 25
Sex
 Male (%) 510 (41.97)
 Female (%) 705 (58.03)
Diagnosis
 Crohn’s Disease (%) 615 (50.62)
 Ulcerative Colitis (%) 495 (40.74)
 IBDU (%) 61 (5.02)
 Other (microscopic colitis, IBDI, reconsidering IBD diagnosis) (%) 44 (3.62)
Montreal Classification
 A: Age of Onset
  A1 (%) 159 (13.09)
  A2 (%) 710 (58.44)
  A3 (%) 253 (20.82)
 L: Disease Location (CD only)
  L1 (%) 224 (36.42)
  L2 (%) 120 (19.51)
  L3 (%) 255 (41.46)
  L4 (%) 65 (10.57)
 B: Disease Behaviour (CD only)
  B1 (%) 301 (48.94)
  B2 (%) 208 (33.82)
  B3 (%) 102 (16.58)
  Perianal 189 (30.73)
 E: Disease Extent (UC only)
  E1 (%) 57 (10.25)
  E2 (%) 162 (29.13)
  E3 (%) 299 (53.78)
 S: Disease Severity (UC only)
  S1 (%) 29 (5.22)
  S2 (%) 139 (25.00)
  S3 (%) 191 (34.35)
  S4 (%) 119 (21.40)
Age at Diagnosis in years (Median ± IQR) 27 ± 19
Disease Duration at Recruitment in years (Median ± IQR) 8 ± 12
Medication Exposure
 Steroids % 90.07
 Steroids CD % 91.99
 Steroids UC % 88.28
 Steroids IBDU % 88.33
 Immunosuppressors % 68.32
 Immunosuppressors CD % 79.08
 Immunosuppressors UC % 56.97
 Immunosuppressors IBDU % 56.67
 Biologicals % 37.30
 Biologicals CD % 55.07
 Biologicals UC % 17.37
 Biologicals IBDU % 25.00
 Mesalazines % 44.34
 Mesalazines CD % 18.06
 Mesalazines UC % 70.99
 Mesalazines IBDU % 83.33
Average Disease Activitya
 HBI (Average ± Standard Deviation) 2.99 ± 3.18
 SSCAI (Average ± Standard Deviation) 1.61 ± 1.97
  1. aFor each patient, the median disease activity was determined. For the entire group the average of the individual medians is presented here
  2. IQR interquartile range, CD Crohn’s disease, UC ulcerative colitis, IBDU inflammatory bowel disease undetermined, IBDI inflammatory bowel disease intermediate, HBI Harvey-Bradshaw Index, SSCAI Simple Clinical Colitis Activity Index